Search details
1.
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
J Neurooncol
; 145(1): 97-105, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31456142
2.
Therapeutic Immunization against Glioblastoma.
Int J Mol Sci
; 19(9)2018 Aug 27.
Article
in English
| MEDLINE | ID: mdl-30150597
3.
Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
CNS Oncol
; 13(1): 2345579, 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38722227
4.
Pembrolizumab in an HIV-infected patient with glioblastoma.
Immunotherapy
; : 1-9, 2024 Jun 18.
Article
in English
| MEDLINE | ID: mdl-38889068
5.
Metastatic glioblastoma to the lungs: a case report and literature review.
CNS Oncol
; 13(1): 2351789, 2024 Jun 06.
Article
in English
| MEDLINE | ID: mdl-38864820
6.
Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
Per Med
; 21(2): 71-78, 2024.
Article
in English
| MEDLINE | ID: mdl-38275171
7.
Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.
Neurol Int
; 14(3): 574-580, 2022 Jun 27.
Article
in English
| MEDLINE | ID: mdl-35893281
8.
Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study.
J Adv Pract Oncol
; 13(8): 775-789, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36727021
9.
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide.
Front Oncol
; 12: 934638, 2022.
Article
in English
| MEDLINE | ID: mdl-35837107
10.
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
J Exp Clin Cancer Res
; 41(1): 344, 2022 Dec 14.
Article
in English
| MEDLINE | ID: mdl-36517865
11.
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas.
Front Neurol
; 11: 373, 2020.
Article
in English
| MEDLINE | ID: mdl-32435228
12.
Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports.
CNS Oncol
; 7(2): CNS09, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29698064
13.
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
CNS Oncol
; 7(3): CNS22, 2018 07 01.
Article
in English
| MEDLINE | ID: mdl-30157683
14.
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
Int J Radiat Oncol Biol Phys
; 100(5): 1195-1203, 2018 04 01.
Article
in English
| MEDLINE | ID: mdl-29722661
15.
Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia.
Case Rep Neurol
; 9(1): 114-120, 2017.
Article
in English
| MEDLINE | ID: mdl-28559835
16.
Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy.
Int Immunopharmacol
; 22(2): 427-43, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25027630
17.
Successful desensitization protocol for delayed cutaneous eruption to temozolomide.
J Allergy Clin Immunol Pract
; 2(5): 626-8, 2014.
Article
in English
| MEDLINE | ID: mdl-25213062
Results
1 -
17
de 17
1
Next >
>>